Ukraine
Tuberculosis profile
| High HIV burden | High MDR-TB burden |
Population  2013 45 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 6.6 (6.4–6.7) 14 (14–15)
Mortality (HIV+TB only) 1.3 (0.96–1.7) 2.8 (2.1–3.7)
Prevalence  (includes HIV+TB) 54 (27–91) 120 (59–202)
Incidence  (includes HIV+TB) 44 (39–50) 96 (87–110)
Incidence (HIV+TB only) 7.2 (7.1–7.2) 16 (16–16)
Case detection, all forms (%) 84 (73–93)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 14 (14–15) 32 (31–33)
MDR-TB cases among notified pulmonary
TB cases
4 100 (3 900–4 300) 5 300 (5 100–5 500)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 16 125   4 443
Pulmonary, clinically diagnosed 12 218   507
Extrapulmonary 3 056   161
       
Total new and relapse 36 510    
Previously treated, excluding relapses 11 624    
Total cases notified 48 134    
Among 36 510 new and relapse cases:
638 (2%) cases aged under 15 years; male:female ratio: 2.5
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 13 056 (81%) 8 619 (52%) 21 675
Laboratory-confirmed RR-/MDR-TB cases     10 585
Patients started on MDR-TB treatment     9 000
TB/HIV 2013 Number (%)
TB patients with known HIV status 42 213 (88)
HIV-positive TB patients 8 290 (20)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 4 092 (49)
HIV-positive TB patients on antiretroviral therapy (ART) 3 949 (48)
HIV-positive people screened for TB    
HIV-positive people provided with IPT 15 816  
Treatment success rate (%)
New and relapse cases registered in 2012 71
Previously treated cases, excluding relapse, registered in 2012 51
HIV-positive TB cases, all types, registered in 2012  
RR-/MDR-TB cases started on second-line treatment in 2011 34
XDR-TB cases started on second-line treatment in 2011  
Laboratories 2013  
Smear (per 100 000 population) 1.8
Culture (per 5 million population) 9.0
Drug susceptibility testing (per 5 million population) 3.5
Sites performing Xpert MTB/RIF 15
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2014  
National TB programme budget (US$ millions) 110
% Funded domestically 31%
% Funded internationally 25%
% Unfunded 44%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-03-06 Data: www.who.int/tb/data